De Novo Malignancies After Liver Transplantation: Incidence Comparison With the Korean Cancer Registry

详细信息	查看全文 | 推荐本文 |

• 作者：H.W. Park ; S. Hwang ; ^{shwang@amc.seoul.kr} ; C.S. Ahn ; K.H. Kim ; D.B. Moon ; T.Y. Ha ; G.W. Song ; D.H. Jung ; G.C. Park ; J.M. Namgoong ; S.Y. Yoon ; C.S. Park ; Y.H. Park ; H.J. Lee ; S.G. Lee
• 刊名：Transplantation Proceedings
• 出版年：2012
• 期刊代码：252_00411345
• 类别：med
• 出版时间：April, 2012
• 卷：44
• 期：3
• 页码：802-805
• 文件大小：116 K

摘要

<h4 class="h4">Purposeh4>De novo malignancy is not uncommon after liver transplantation (OLT). We have compared the incidence of novo malignancy following OLT with those among the general Korean population.<h4 class="h4">Methodsh4>

Between January 1998 and December 2008, 1952 adult OLT were performed, including 1714 living donor and 238 deceased donor grafts whose medical records were retrospectively reviewed.<h4 class="h4">Resultsh4>

Among the 1952 patients, 44 (2.3%) showed de novo malignancies after a mean posttransplant period of 41 months. Among the 14 types of malignancy the most frequent was stomach cancer (n = 11; 25.0%), colorectal cancer (n = 9; 20.5%), breast cancer (n = 4; 9.1%), and thyroid cancer (n = 3; 6.8%). These patients underwent aggressive treatment, including surgery, chemotherapy, and radiotherapy, except for one patient with an aggressive primary liver cancer. Over a mean follow-up of 45 months after diagnosis of de novo malignancy, 13 patients (29.5%) died; the overall 3-year patient survival rate was 67.5%. The relative risk of malignancy following OLT was 7.7-fold higher in men and 7.3-fold higher in women than the Korean general population.<h4 class="h4">Conclusionsh4>

OLT recipients must be checked periodically for de novo malignancy throughout their lives, especially for cancers common in the general population.